US 12,459,999 B2
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
Stephen James Moore, Danville, CA (US); Margaret Thy Luu Nguyen, San Francisco, CA (US); Daniel Robert Hostetter, Palo Alto, CA (US); Olga Vasiljeva, Cupertino, CA (US); Jason Gary Sagert, San Mateo, CA (US); Jonathan Alexander Terrett, Cupertino, CA (US); and James William West, Bend, OR (US)
Assigned to CYTOMX THERAPEUTICS, INC., South San Francisco, CA (US)
Filed by CytomX Therapeutics, Inc., South San Francisco, CA (US)
Filed on Dec. 7, 2022, as Appl. No. 18/062,619.
Application 18/062,619 is a division of application No. 17/360,809, filed on Jun. 28, 2021, granted, now 11,548,944.
Application 17/360,809 is a division of application No. 15/002,131, filed on Jan. 20, 2016, granted, now 11,046,759, issued on Jun. 29, 2021.
Claims priority of provisional application 62/278,713, filed on Jan. 14, 2016.
Claims priority of provisional application 62/277,771, filed on Jan. 12, 2016.
Claims priority of provisional application 62/258,015, filed on Nov. 20, 2015.
Claims priority of provisional application 62/105,490, filed on Jan. 20, 2015.
Prior Publication US 2023/0212283 A1, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/00 (2006.01); A61K 38/05 (2006.01); A61K 47/68 (2017.01); A61K 49/00 (2006.01); C07K 7/08 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/28 (2013.01) [A61K 38/05 (2013.01); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 49/0058 (2013.01); C07K 7/08 (2013.01); C07K 14/00 (2013.01); C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/92 (2013.01); C07K 2319/50 (2013.01); C07K 2319/74 (2013.01)] 8 Claims
 
1. An isolated polypeptide comprising a cleavable moiety (CM), wherein the CM comprises the amino acid sequence ISSGLLSGRSANPRG (SEQ ID NO: 469).